Femtomolar Fab binding affinities to a protein target by alternative CDR residue co-optimization strategies without

Christian Votsmeier1, Hanna Plittersdorf, Oliver Hesse

  • 1Global Drug Discovery, Global Biologics, Bayer HealthCare AG, Cologne, Germany. christian.votsmeier@bayer.com

Mabs
|April 26, 2012
PubMed

Related Concept Videos